Hello JITC Readers,

Our original research article highlight this month includes four exciting papers that make progress toward overcoming longstanding challenges in our field: eliciting systemic immune responses to local therapy and serum-based biomarkers for tumor response.
Robert B Rebhun and colleagues report a clinical benefit rate of 39% with minimal systemic toxicity in a first-in-canine phase I clinical trial evaluating inhaled recombinant human IL-15 for the treatment of spontaneous melanoma or osteosarcoma in companion dogs.
Regression of untreated lesions in murine melanoma models with local injection of a hydrogel carrying a lysate of the bacterial immunotherapy Mycobacterium bovis Bacillus Calmette-Guérin is described by Mirela Kremenovic et al.
An almost 80% overall response rate to checkpoint blockade in pancreatic ductal adenocarcinoma identified as microsatellite instability-high through ctDNA analysis is observed in a retrospective analysis by Sakti Chakrabarti and colleagues.
Michal Harel et al leverage machine learning and longitudinal plasma proteomic profiling to identify a signature based on age, sex, and on-treatment serum levels of CXCL18 and CXCL10 to predict benefit with anti-PD-1 in non-small cell lung cancer.
If you’re looking for more reading material, this month’s selections from JITC’s archives include some of the top case reports and commentary/editorials over the years.
Best wishes,
Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer
Editor-in-Chief, Journal for ImmunoTherapy of Cancer